Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05988658 · ClinicalTrials.gov registry record
Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients
A clinical trial of Acute Kidney Injury and Biomarkers, sponsored by University of Chicago.
- Recruiting
- Registry status
- 800
- Enrollment target
- 2
- Study locations
NCT05988658 is a study of Acute Kidney Injury and Biomarkers that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 800 participants, below the 2,320-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05988658, a study of Acute Kidney Injury and Biomarkers, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study's objective is to evaluate the additive value of renal biomarkers (from blood and urine) for identifying individuals at high risk for severe acute kidney injury (AKI) above that of a novel natural language processing (NLP)-based AKI risk algorithm. The risk algorithm is based on electronic health records (EHR) data (labs, vitals, clinical notes, and test reports). Patients will enroll at the University of Chicago Medical Center and the University of Wisconsin Hospital, where the risk score will run in real time. The risk score will identify those patients with the highest risk for the future development of Stage 2 AKI and collect blood and urine for biomarker measurement over the subsequent 3 days.
Conditions Studied
Interventions
- DEVICE ESTOP - AKI 2.0
Study Locations (2)
Illinois
- University of Chicago Medical Center - Chicago
Wisconsin
- University of Wisconsin Hospital - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2024-01-05 |
| Est. Completion | 2028-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05988658
The ClinicalTrials.gov registry entry for NCT05988658 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,320-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (66% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 1 intervention - of which ESTOP - AKI 2.0 is the first listed.
NCT05988658 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05988658 about?
NCT05988658 is a clinical study titled "Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients". The study's objective is to evaluate the additive value of renal biomarkers (from blood and urine) for identifying individuals at high risk for severe acute kidney injury (AKI) above that of a novel natural language processing (NLP)-based AKI risk algorithm. The risk algorithm is based on electronic...
What is the current status of trial NCT05988658?
This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2024-01-05. Estimated completion is 2028-03-01.
What conditions does trial NCT05988658 study?
This clinical trial studies the following conditions: Acute Kidney Injury, Biomarkers.
What interventions are being tested in trial NCT05988658?
The interventions under investigation include: ESTOP - AKI 2.0 (DEVICE).
Who is sponsoring clinical trial NCT05988658?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05988658 being conducted?
This trial has 2 study locations across Illinois, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
RECRUITING
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.